Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTR707 + Rituximab in R/R CD20+ B-cell Lymphoma
NCT03189836Phase 1Terminated
- Sponsor
- Cogent Biosciences
- Start
- Oct 2017
- Primary completion
- Sep 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of ACTR707 in B cell lymphoma, sponsored by Cogent Biosciences. Primary endpoints: Safety as assessed by dose limiting toxicities (DLTs) at 28 days and Maximum Tolerated Dose and Recommended Phase 2 Dose at 24 weeks. Started Oct 2017; status: terminated.
02
Drugs
ACTR707
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03189836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03189836.